PortfoliosLab logoPortfoliosLab logo
ISIN
US92243A2006
CUSIP
92243A200
IPO Date
Feb 12, 2018

Highlights

Market Cap
$129.57M
Enterprise Value
$89.32M
EPS (TTM)
$0.16
PE Ratio
3.35
PEG Ratio
0.01
Total Revenue (TTM)
$255.61M
Gross Profit (TTM)
$193.63M
EBITDA (TTM)
$45.63M
Year Range
$0.26 - $0.84
Target Price
$2.00
ROA (TTM)
20.60%
ROE (TTM)
39.42%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

VXRT Performance Chart

Vaxart, Inc. (VXRT) is up 54.5% since the beginning of the year. At $1 per share, VXRT is trading 36.7% below its 52-week high of $1. Investors who bought $1,000 worth of VXRT shares 5 years ago would now be looking at an investment worth $68.


Loading charts...

S&P 500 Index

Returns By Period

Vaxart, Inc. (VXRT) has returned 54.45% so far this year and -7.76% over the past 12 months.


Vaxart, Inc.

1D
-2.90%
1M
-17.03%
YTD
54.45%
6M
49.61%
1Y
-7.76%
3Y*
-15.24%
5Y*
-41.56%
10Y*

Benchmark (S&P 500 Index)

1D
-0.37%
1M
-0.01%
YTD
9.16%
6M
8.64%
1Y
25.22%
3Y*
19.78%
5Y*
11.99%
10Y*
13.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

VXRT Monthly Returns History

Based on dividend-adjusted daily data since Feb 12, 2018, VXRT's average daily return is +0.17%, while the average monthly return is +3.93%. At this rate, an investment would double in approximately 1.5 years.

Historically, 46% of months were positive and 54% were negative. The best month was Jan 2020 with a return of +256.6%, while the worst month was Apr 2019 at -61.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, VXRT closed higher 44% of trading days. The best single day was Jun 25, 2020 with a return of +96.2%, while the worst single day was Feb 3, 2021 at -57.8%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202667.38%37.12%-23.90%27.27%-16.23%-17.05%54.45%
20252.67%-25.08%-20.09%8.01%-1.48%4.36%-18.14%5.41%-6.45%-8.29%10.58%-6.38%-47.68%
2024106.01%3.39%6.56%-45.02%14.03%-18.12%0.66%29.06%-2.06%-9.86%-21.60%10.35%15.59%
202312.39%-27.83%-2.91%7.51%49.97%-40.16%12.08%0.54%-8.34%-12.39%8.23%-19.89%-40.39%
2022-21.05%2.63%-0.79%-30.95%4.60%-3.85%5.14%-15.76%-29.68%-23.39%-29.34%-18.57%-84.67%
2021109.81%-40.32%-15.38%78.18%-38.59%13.14%-4.01%24.48%-11.17%-15.60%18.63%-21.23%9.81%

Benchmark Metrics

Vaxart, Inc. has an annualized alpha of 38.74%, beta of 0.66, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 12, 2018.

  • This stock participated in 103.78% of S&P 500 Index downside but only -35.15% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.66 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
38.74%
Beta
0.66
0.01
Upside Capture
-35.15%
Downside Capture
103.78%

Return for Risk

Risk / Return Rank

VXRT ranks 41 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.


VXRT Risk / Return Rank: 4141
Overall Rank
VXRT Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
VXRT Sortino Ratio Rank: 4747
Sortino Ratio Rank
VXRT Omega Ratio Rank: 4848
Omega Ratio Rank
VXRT Calmar Ratio Rank: 3737
Calmar Ratio Rank
VXRT Martin Ratio Rank: 3737
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Vaxart, Inc. (VXRT) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


VXRTBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-2.11

Sortino ratioReturn per unit of downside risk

-2.11

Omega ratioGain probability vs. loss probability

1.09

1.37

-0.28

Calmar ratioReturn relative to maximum drawdown

-0.17

2.78

-2.95

Martin ratioReturn relative to average drawdown

-0.28

12.44

-12.72

Dividends

Dividend History


Vaxart, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Vaxart, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vaxart, Inc. was 98.71%, occurring on Jul 9, 2025. The portfolio has not yet recovered.

The current Vaxart, Inc. drawdown is 97.71%.


Related event

Drawdown

Fall

Recovery

Underwater

2025 bear market2025
-98.71%Jul 2025
4y 5mo
5y 4moFeb 2021 - now
2019 bear market2019
-96.95%Nov 2019
1y 9mo7mo 24d
2y 5moFeb 2018 - Jul 2020
2020 bear market2020
-79.38%Nov 2020
3mo 27d2mo 25d
6mo 22dJul 2020 - Feb 2021

Drawdown Indicators


VXRTBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-98.71%

-56.78%

-41.93%

Max Drawdown (1Y)

Largest decline over 1 year

-46.47%

-9.10%

-37.37%

Max Drawdown (3Y)

Largest decline over 3 years

-78.72%

-18.90%

-59.82%

Max Drawdown (5Y)

Largest decline over 5 years

-96.94%

-25.43%

-71.51%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-97.71%

-1.80%

-95.91%

Average Drawdown

Average peak-to-trough decline

-82.98%

-10.71%

-72.27%

Ulcer Index

Depth and duration of drawdowns from previous peaks

29.23%

2.03%

+27.20%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Vaxart, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Vaxart, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for VXRT, comparing it with other companies in the Biotechnology industry. Currently, VXRT has a P/E ratio of 3.4. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for VXRT compared to other companies in the Biotechnology industry. VXRT currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for VXRT relative to other companies in the Biotechnology industry. Currently, VXRT has a P/S ratio of 0.5. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for VXRT in comparison with other companies in the Biotechnology industry. Currently, VXRT has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with VXRT

Add Vaxart, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with VXRT